Cortexyme Expands Clinical Advisory Board With Key Clinical and Regulatory Experts
June 19, 2019SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical
company pioneering a novel disease-modifying therapeutic approach to
treat a key underlying cause of Alzheimer’s and other degenerative
diseases, today announced four new additions to its Clinical
Advisory Board (CAB). Jeffrey Cummings, M.D., Sc.D., David Hosford M.D.,
Ph.D., Lon Schneider, M.D., M.S., and Pierre N. Tariot, M.D. join the
CAB with deep and diverse experience in central nervous system (CNS)
drug development. The newly expanded CAB will support Cortexyme as its
lead investigational gingipain inhibitor, COR388, moves through phase
2/3 clinical development as a potential treatment for patients with mild
to moderate Alzheimer’s disease.
“The growing data from Cortexyme and other researchers around the
gingipain hypothesis is compelling,” said Lon Schneider, M.D., M.S., a
new member of the CAB and Professor of Psychiatry, Neurology, and
Gerontology at the Keck School of Medicine of the University of Southern
California. “I look forward to collaborating with my colleagues on the
Cortexyme CAB to advise the company as it evaluates this upstream
therapeutic approach, both through the ongoing GAIN trial and future
clinical development work.”
Commenting on the expansion of the CAB, Michael Detke, M.D., Ph.D.,
Chief Medical Officer of Cortexyme said: “Cortexyme has benefited
greatly from our Clinical Advisory Board’s input into the GAIN trial
design, and we are excited to expand the group with the addition of Drs.
Cummings, Hosford, Schneider, and Tariot, who collectively bring
world-class expertise in CNS disease research, drug development, and
regulatory affairs. We look forward to working together to efficiently
advance COR388 for the benefit of Alzheimer’s patients.”
Additions to Cortexyme’s Clinical Advisory Board:
-
Jeffrey Cummings, M.D., Sc.D., is a longtime Alzheimer’s
researcher and clinical trial leader committed to developing new
therapies for diseases of the brain and studying the interface of
neuroscience and society. Dr. Cummings is Research Professor in the
Department of Brain Health at University of Nevada Las Vegas and
founding director of Cleveland Clinic Lou Ruvo Center for Brain Health
in Las Vegas, Nevada and Cleveland, Ohio. He is a professor of
medicine (neurology) at the Cleveland Clinic Lerner College of
Medicine of Case Western Reserve University. He is the principal
investigator/director of the NIH/NIGMS-funded Center for
Neurodegeneration and Translational Neuroscience. -
David Hosford M.D., Ph.D. is the chief medical officer (CMO) at
Kingsfoil Pharmavision, a biopharmaceutical consultancy specializing
in strategic drug development advice and regulatory pathway guidance.
He formerly served as an FDA clinical reviewer in its Division of
Neurology Products; as CMO at Kowa Research Institute; as a senior
strategic medical lead (CNS) at Quintiles; as the Vice President for
Clinical Development and Regulatory Affairs at Targacept, Inc.; and in
many discovery and development roles across multiple therapeutic areas
at GlaxoSmithKline. -
Lon Schneider, M.D., M.S. is a recognized expert on Alzheimer’s
disease and its treatment, late-in-life depression, and drug
development. He is a professor of Psychiatry, Neurology, and
Gerontology at the Keck School of Medicine of the University of
Southern California. Dr. Schneider also serves as the director of the
California Alzheimer’s Disease Center and the USC Department of
Psychiatry Geriatric Studies Center, as well as the co-director of the
clinical core of the university’s Alzheimer’s Disease Research Center,
which is supported by the NIH. -
Pierre N. Tariot, M.D. serves as the director of the Banner
Alzheimer’s Institute, a component of the research organization of
Banner Health, one of the largest non-profit healthcare systems in the
United States. Dr. Tariot is also a research professor of psychiatry
at the University of Arizona College of Medicine. A member of the
American College of Neuropsychopharmacology, he has earned multiple
awards for his research, including the American Geriatrics Society
New Investigator Award for Neuroscience and an NIMH Geriatric Mental
Health Academic Award.
About Cortexyme, Inc.
Cortexyme (Nasdaq: CRTX) is a clinical stage biopharmaceutical company
pioneering a novel disease-modifying therapeutic approach to treat a key
underlying cause of Alzheimer’s disease and other degenerative
diseases. Cortexyme is targeting a specific, infectious pathogen found
in the brain of Alzheimer’s patients and tied to neurodegeneration and
neuroinflammation in animal models. The company’s lead investigational
medicine, COR388, is the subject of the GAIN trial, an ongoing Phase 2/3
clinical study in patients with mild to moderate Alzheimer’s disease.
More information about the trial can be found at www.GAINtrial.com.
To learn more about Cortexyme, visit www.cortexyme.com.
Forward-Looking Statements
Statements in this press release contain “forward-looking statements”
that are subject to substantial risks and uncertainties. Forward-looking
statements contained in this press release may be identified by the use
of words such as “anticipate,” “expect,” “believe,” “will,” “may,”
“should,” “estimate,” “project,” “outlook,” “forecast” or other similar
words. Forward-looking statements are based on Cortexyme’s current
expectations and are subject to inherent uncertainties, risks and
assumptions that are difficult to predict. Further, certain
forward-looking statements are based on assumptions as to future events
that may not prove to be accurate. Factors that could cause actual
results to differ include, but are not limited to, the risks and
uncertainties described in the section titled “Risk Factors” in the
final prospectus related to Cortexyme’s initial public offering filed
with the Securities and Exchange Commission on May 9, 2019 and Quarterly
Report on Form 10-Q filed with the Securities and Exchange Commission on
June 12, 2019. Forward-looking statements contained in this press
release are made as of this date, and Cortexyme undertakes no duty to
update such information except as required under applicable law.
Contacts
Hal Mackins
For Cortexyme, Inc.
[email protected]
(415)
994-0040
